Skip to main content
Clinical Trials/NCT04972799
NCT04972799
Recruiting
Not Applicable

AUTOGRAFI : Evaluation of the Efficacy and Safety of Autologous Fat Injection Into the Intersphincter Space in Fecal Incontinence: a Randomized, Placebo-controlled, Cross-over, Double-blind Trial

Rennes University Hospital3 sites in 1 country50 target enrollmentOctober 19, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fecal Incontinence
Sponsor
Rennes University Hospital
Enrollment
50
Locations
3
Primary Endpoint
Number of fecal incontinence events
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Fecal incontinence is frequent and has a significant impact on the quality of life of individuals. Its therapeutic management is based primarily on transit regulation and rehabilitation and secondarily on neuromodulation of the sacral roots. However, this strategy is insufficient in more than one patient out of three. The patient and the clinician are often at a loss and the therapeutic possibilities are limited to the use of evacuating enemas and/or a colostomy.

The practice of autologous fat injections was initially developed in plastic surgery. The studies that have evaluated the efficacy of autologous fat injections in fecal incontinence in men are preliminary and old isolated observations. However, they have shown an improvement in episodes of fecal incontinence and in sphincter parameters. In the field of proctology and autologous fat injections, 2 recent small open studies have evaluated the efficacy and morbidity of this therapy in the treatment of anal fistulas related to Crohn's disease.

The primary hypothesis of the work is that autografting adipose tissue into the intersphincteric space can decrease episodes of fecal incontinence in patients with severe fecal incontinence due to sphincter failure. The secondary hypotheses are that autograft of adipose tissue in the intersphincter space improves resting anal pressures, is a well-tolerated technique for patients, and may improve their quality of life.

Registry
clinicaltrials.gov
Start Date
October 19, 2022
End Date
November 2027
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Rennes University Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • severe fecal incontinence characterized by at least one episode of weekly fecal incontinence
  • failed rehabilitation and dietary management strategies
  • who have failed/contraindicated/refused sacral root neuromodulation (in the indication of fecal incontinence)
  • having, for women of childbearing age, effective contraception throughout the study
  • having given free, informed and written consent

Exclusion Criteria

  • unable or unwilling to undergo follow-up or symptomatic evaluation
  • contraindication to general anesthesia
  • contraindication to metronidazole (hypersensitivity and wheat allergy)
  • significant pelvic static disorder
  • active anal suppuration
  • anal stenosis
  • externalized rectal prolapse
  • chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis)
  • on anticoagulants or antiaggregants
  • history of anal or rectal neoplasia

Outcomes

Primary Outcomes

Number of fecal incontinence events

Time Frame: 3 months

Change from baseline in number of fecal incontinence events at 3 months

Study Sites (3)

Loading locations...

Similar Trials